| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/10408363.2011.591365 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.3109/10408363.2011.591365 |
| P698 | PubMed publication ID | 21871000 |
| P2093 | author name string | Nima Alamdari | |
| Per-Olof Hasselgren | |||
| Zaira Aversa | |||
| P2860 | cites work | Myostatin mutation associated with gross muscle hypertrophy in a child | Q24297666 |
| The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription | Q24301955 | ||
| Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase | Q24310456 | ||
| IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a | Q24336832 | ||
| Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo | Q24530035 | ||
| CCAAT/enhancer-binding proteins: structure, function and regulation | Q24534323 | ||
| Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation | Q24534597 | ||
| Histone deacetylases (HDACs): characterization of the classical HDAC family | Q24535587 | ||
| Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy | Q24555065 | ||
| SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator | Q24626329 | ||
| Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy | Q24634396 | ||
| Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes | Q24645537 | ||
| The role of chromatin during transcription | Q27860995 | ||
| Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases | Q28189618 | ||
| Protein degradation by the ubiquitin-proteasome pathway in normal and disease states | Q28243121 | ||
| Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: Mechanisms at the cellular and molecular levels | Q57973298 | ||
| Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle | Q73208228 | ||
| The transcription factors NF-kappab and AP-1 are differentially regulated in skeletal muscle during sepsis | Q73598526 | ||
| Insulin-like growth factor I reduces ubiquitin and ubiquitin-conjugating enzyme gene expression but does not inhibit muscle proteolysis in septic rats | Q74086347 | ||
| Does ICU-acquired paresis lengthen weaning from mechanical ventilation? | Q75437314 | ||
| Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis | Q79373532 | ||
| Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I | Q80198869 | ||
| Respiratory weakness is associated with limb weakness and delayed weaning in critical illness | Q81251477 | ||
| Expression and activity of C/EBPbeta and delta are upregulated by dexamethasone in skeletal muscle | Q81315131 | ||
| Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism | Q81598069 | ||
| Exercise stimulates Pgc-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway | Q40446884 | ||
| IKKbeta/NF-kappaB activation causes severe muscle wasting in mice | Q40505119 | ||
| The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors | Q40559475 | ||
| PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. | Q40572600 | ||
| Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells | Q40649634 | ||
| Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products | Q40690105 | ||
| Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin | Q41057436 | ||
| Diabetes-induced atrophy is associated with a muscle-specific alteration in NF-kappaB activation and expression | Q41809945 | ||
| Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation | Q42009070 | ||
| NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight | Q42072500 | ||
| C/EBPβ regulates dexamethasone‐induced muscle cell atrophy and expression of atrogin‐1 and MuRF1 | Q42144502 | ||
| Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase | Q42169148 | ||
| Endotoxin triggers nuclear factor-kappaB-dependent up-regulation of multiple proinflammatory genes in the diaphragm | Q42496888 | ||
| Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases | Q42504415 | ||
| CCAAT/enhancer-binding protein (C/EBP) beta is acetylated at multiple lysines: acetylation of C/EBPbeta at lysine 39 modulates its ability to activate transcription | Q42833598 | ||
| Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle | Q42949695 | ||
| Gender differences in pediatric burn patients: does it make a difference? | Q44198339 | ||
| Functional improvement of dystrophic muscle by myostatin blockade. | Q44234792 | ||
| Mechanism of p300 specific histone acetyltransferase inhibition by small molecules | Q44253162 | ||
| Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control | Q44991663 | ||
| Overexpression of the transcriptional coregulator Cited2 protects against glucocorticoid-induced atrophy of C2C12 myotubes. | Q46229145 | ||
| Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor i and glycogen synthase kinase-3beta inhibitors | Q46414798 | ||
| Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle | Q46681308 | ||
| Relative contributions of muscle activation and muscle size to plantarflexor torque during rehabilitation after immobilization | Q47333440 | ||
| Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss | Q47392020 | ||
| Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy | Q48015891 | ||
| Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor | Q51455030 | ||
| Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism | Q51805331 | ||
| CBP/p300 and muscle differentiation: no HAT, no muscle | Q39646212 | ||
| Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity | Q39714611 | ||
| Sepsis increases the expression and activity of the transcription factor Forkhead Box O 1 (FOXO1) in skeletal muscle by a glucocorticoid-dependent mechanism | Q39751365 | ||
| Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice | Q40077801 | ||
| The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle | Q40190344 | ||
| Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors | Q40248450 | ||
| C/EBP beta blocks p65 phosphorylation and thereby NF-kappa B-mediated transcription in TNF-tolerant cells | Q40265408 | ||
| Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression | Q40321294 | ||
| Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions | Q40364656 | ||
| Glucocorticoids increase C/EBPbeta activity in the lung epithelium via phosphorylation | Q40399083 | ||
| Endogenous CCAAT/enhancer binding protein beta and p300 are both regulated by growth hormone to mediate transcriptional activation. | Q40429361 | ||
| Malnutrition and wasting in renal disease | Q28246508 | ||
| Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha | Q28513388 | ||
| C/EBP DNA-binding activity is upregulated by a glucocorticoid-dependent mechanism in septic muscle | Q28565301 | ||
| Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression | Q28565720 | ||
| Dexamethasone-induced protein degradation in cultured myotubes is p300/HAT dependent | Q28570470 | ||
| Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle | Q28574576 | ||
| Differential adaptation of growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia inhibitory factor in overloaded, regenerating and denervated rat muscles | Q28581030 | ||
| Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy | Q28582211 | ||
| Shared principles in NF-kappaB signaling | Q29547234 | ||
| Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres | Q29555845 | ||
| FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells | Q29614482 | ||
| FoxO3 controls autophagy in skeletal muscle in vivo | Q29614483 | ||
| Specificity and versatility in tgf-beta signaling through Smads | Q29616324 | ||
| Metabolic control through the PGC-1 family of transcription coactivators | Q29616509 | ||
| Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy | Q29619282 | ||
| AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha | Q29620443 | ||
| Ros-mediated activation of NF-kappaB and Foxo during muscle disuse | Q33551292 | ||
| Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines | Q33588112 | ||
| Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor | Q33599508 | ||
| Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation | Q33855408 | ||
| Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis | Q33896013 | ||
| Calcineurin signaling and PGC-1alpha expression are suppressed during muscle atrophy due to diabetes | Q33912897 | ||
| Mechanisms to explain wasting of muscle and fat in cancer cachexia | Q34013222 | ||
| Mechanisms of cancer cachexia | Q34016887 | ||
| FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy | Q34017130 | ||
| Control of muscle development by dueling HATs and HDACs | Q34088887 | ||
| Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylation | Q34115660 | ||
| How do 14-3-3 proteins work?-- Gatekeeper phosphorylation and the molecular anvil hypothesis | Q34120299 | ||
| Sepsis and glucocorticoids downregulate the expression of the nuclear cofactor PGC-1beta in skeletal muscle | Q34215201 | ||
| Nuclear receptors, coactivators and chromatin: new approaches, new insights | Q34276963 | ||
| Ubiquitin ligase gene expression in healthy volunteers with 20-day bedrest | Q34551151 | ||
| PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription | Q34575428 | ||
| Nuclear factor-kappa B signaling in skeletal muscle atrophy. | Q34593476 | ||
| Smad2 and 3 transcription factors control muscle mass in adulthood. | Q34606381 | ||
| Retracted: Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging | Q34613904 | ||
| Regulation of muscle protein synthesis during sepsis and inflammation | Q34628735 | ||
| Ubiquitination, phosphorylation, and acetylation--triple threat in muscle wasting | Q34656599 | ||
| Regulation of protein turnover by acetyltransferases and deacetylases. | Q34660218 | ||
| Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. | Q34764722 | ||
| Regulating the regulators: lysine modifications make their mark | Q35044538 | ||
| Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients | Q35111740 | ||
| Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation | Q35200617 | ||
| Effect of phosphorylation and S-S bond-induced dimerization on DNA binding and transcriptional activation by C/EBPbeta | Q35629382 | ||
| PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. | Q35720854 | ||
| Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability | Q36072174 | ||
| Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies | Q36202135 | ||
| Novel aspects on the regulation of muscle wasting in sepsis | Q36241903 | ||
| The cancer cachexia syndrome: a review of metabolic and clinical manifestations | Q36278394 | ||
| Muscle regeneration through myostatin inhibition | Q36285801 | ||
| The NF-kappaB inhibitor curcumin blocks sepsis-induced muscle proteolysis | Q36517738 | ||
| Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation | Q36534424 | ||
| Counteracting muscle wasting in HIV-infected individuals. | Q36582724 | ||
| Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors | Q36670010 | ||
| Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? | Q36694116 | ||
| Therapeutic approaches for muscle wasting disorders | Q36720401 | ||
| Calpain activity and muscle wasting in sepsis | Q36956035 | ||
| The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy | Q37072407 | ||
| Mechanisms of neuromuscular dysfunction in critical illness | Q37074454 | ||
| PGC-1 coactivators and skeletal muscle adaptations in health and disease | Q37265277 | ||
| Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease | Q37280594 | ||
| Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology | Q37286190 | ||
| Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins | Q37535142 | ||
| Getting to first base in proteasome assembly | Q37549442 | ||
| Physical inactivity and muscle weakness in the critically ill. | Q37666343 | ||
| Sepsis-induced myopathy | Q37666348 | ||
| Legacy of intensive care unit-acquired weakness | Q37666417 | ||
| Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children | Q37674052 | ||
| Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy | Q37678747 | ||
| Signaling pathways perturbing muscle mass | Q37732100 | ||
| Dexamethasone upregulates the expression of the nuclear cofactor p300 and its interaction with C/EBPbeta in cultured myotubes | Q38331467 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | regulation of gene expression | Q411391 |
| sepsis | Q183134 | ||
| P304 | page(s) | 71-86 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Critical Reviews in Clinical Laboratory Sciences | Q5186664 |
| P1476 | title | Molecules modulating gene transcription during muscle wasting in cancer, sepsis, and other critical illness | |
| P478 | volume | 48 |
| Q39226505 | CaMKII activity is reduced in skeletal muscle during sepsis |
| Q44315702 | MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis |
| Q34652034 | PPARβ/δ Regulates Glucocorticoid- and Sepsis-Induced FOXO1 Activation and Muscle Wasting |
| Q33988273 | Role of IGF-I and the TNFα/NF-κB pathway in the induction of muscle atrogenes by acute inflammation |
| Q45793471 | Role of sepsis in the development of limb muscle weakness in a porcine intensive care unit model |
| Q91949919 | Sepsis-associated pathways segregate cancer groups |
| Q47983891 | Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes |
| Q39330164 | β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophy |
Search more.